Organogenesis Holdings Inc. SEC filings ORGO
Organogenesis Holdings Inc. has 673 filings in SEC EDGAR's recent list, going back to Dec 18, 2015. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 20, 2024 | — |
| CORRESP | Letter to the SEC | Dec 20, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2024 | — |
| D | Filing | Nov 27, 2024 | — |
| EFFECT | Filing | Aug 15, 2024 | — |
| CORRESP | Letter to the SEC | Aug 13, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2024 | — |
| EFFECT | Filing | Nov 12, 2020 | — |
| CORRESP | Letter to the SEC | Nov 10, 2020 | — |
| CORRESP | Letter to the SEC | Nov 10, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 22, 2020 | — |
| EFFECT | Filing | Sep 23, 2019 | — |
| CORRESP | Letter to the SEC | Sep 19, 2019 | — |
| CORRESP | Letter to the SEC | Sep 16, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 10, 2019 | — |
| SC TO-I/A | Filing | Aug 19, 2019 | — |
| SC TO-I/A | Filing | Aug 9, 2019 | — |
| SC TO-I/A | Filing | Jul 22, 2019 | — |
| SC TO-C | 8-k | Jul 16, 2019 | — |
| SC TO-I | Filing | Jul 12, 2019 | — |
| 25-NSE | Delisting notice | Mar 12, 2019 | — |
| EFFECT | Filing | Feb 12, 2019 | — |
| CT ORDER | Filing | Feb 11, 2019 | — |
| 25-NSE | Delisting notice | Dec 14, 2018 | — |
| 8-K12G3 | Filing | Dec 14, 2018 | Dec 10, 2018 |
| CT ORDER | Filing | Dec 3, 2018 | — |
| EFFECT | Filing | Nov 30, 2018 | — |
| CORRESP | Letter to the SEC | Nov 28, 2018 | — |
| CORRESP | Letter to the SEC | Nov 28, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 28, 2018 | — |
| CORRESP | Letter to the SEC | Nov 19, 2018 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2018 | — |
| CORRESP | Letter to the SEC | Nov 2, 2018 | — |
| 425 | 8-k | Oct 30, 2018 | — |
| 425 | 8-k/a | Oct 30, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2018 | — |
| 425 | 8-k | Oct 9, 2018 | — |
| CORRESP | Letter to the SEC | Oct 5, 2018 | — |
| 425 | 8-k | Oct 4, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 1, 2018 | — |
| 425 | 8-k | Aug 30, 2018 | — |
| RW | Filing | Aug 29, 2018 | — |
| 425 | 8-k | Aug 17, 2018 | — |
| 425 | 8-k | Feb 14, 2018 | — |
| 425 | Filing | Feb 9, 2018 | — |
| 425 | 8-k | Feb 9, 2018 | — |
| 425 | 8-k | Jan 22, 2018 | — |
| 425 | Roadshow presentation | Jan 22, 2018 | — |
| 425 | 8-k | Jan 9, 2018 | — |
| 425 | Filing | Jan 4, 2018 | — |
| 425 | Filing | Jan 2, 2018 | — |
| 425 | 8-k | Dec 26, 2017 | — |
| 425 | Filing | Dec 12, 2017 | — |
| EFFECT | Filing | Oct 7, 2016 | — |
| CERTNAS | Auto-generated paper document | Oct 7, 2016 | — |
| 8-A12B | Filing | Oct 5, 2016 | — |
| CORRESP | Letter to the SEC | Oct 5, 2016 | — |
| CORRESP | Letter to the SEC | Oct 5, 2016 | — |
| CORRESP | Letter to the SEC | Sep 15, 2016 | — |
| DRSLTR | Filing | Mar 18, 2016 | — |
| DRS/A | Filing | Mar 18, 2016 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2016 | — |
| DRSLTR | Filing | Feb 5, 2016 | — |
| DRS/A | Filing | Feb 5, 2016 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2016 | — |
| DRS | Filing | Dec 18, 2015 | — |
Showing 66 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORGO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Canton, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1661181
- Former names
- Avista Healthcare Public Acquisition Corp. (until Dec 10, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.